Schott Pharma Cuts Medium-Term Guidance as US Anti-Vaccine Sentiment and Customer Pullback Dampen Growth Prospects
Vaccine hesitancy and major customer order cuts force pharma packager downgrade.
Pharmaceutical packaging manufacturer Schott Pharma is facing mounting pressure from declining vaccination demand and customer order reductions, forcing the company to significantly lower its medium-term financial outlook. The Mainz-based producer of vials, ampoules, and syringes cited growing vaccine hesitancy in the United States
US and a major customer's sharp cutback in prefilled glass syringe orders as key factors behind the downgrade.
US and a major customer's sharp cutback in prefilled glass syringe orders as key factors behind the downgrade.We are seeing dampened expectations in the vaccination and mRNA space, Chief Financial Officer Reinhard Mayerreinhard mayer said Thursday during the presentation of final results for fiscal year 2024/25. CEO Andreas Reisseandreas reisse acknowledged a slight dampening effect from the US issue in the low single-digit percentage range, pointing to the spread of anti-vaccine rhetoric and misinformation that has fueled growing skepticism among the American population.
